How many 8-K filings has Werewolf Therapeutics, Inc. filed?

Werewolf Therapeutics, Inc. (HOWL) has 13 8-K (Current Event Report) filings on record, spanning Jan 2024 to Mar 2026.

What is a 8-K filing?

A 8-K is an SEC filing known as "Current Event Report." Filed to announce significant events or material changes such as acquisitions, executive departures, earnings announcements, or bankruptcy filings.

Where can I read Werewolf Therapeutics, Inc. 8-K filings in plain English?

ReadTheFiling provides AI-powered plain-English summaries of all Werewolf Therapeutics, Inc. 8-K filings, including risk assessment, sentiment analysis, and key financial figures.

Werewolf Therapeutics, Inc. (HOWL) — 8-K Filings

All 8-K filings from Werewolf Therapeutics, Inc.. Browse 13 Current Event Report reports with AI-powered summaries and risk analysis.

8-K Filings (13)

Werewolf Therapeutics Files 8-K for Financial Results — Mar 27, 2026 Risk: low
Werewolf Therapeutics, Inc. filed an 8-K on March 27, 2026, reporting results of operations and financial condition. The filing includes financial statements an
8-K Filing — Dec 18, 2025
Werewolf Therapeutics Faces Delisting Concerns — Oct 6, 2025 Risk: high
Werewolf Therapeutics, Inc. filed an 8-K on October 6, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule. The earliest event
Werewolf Therapeutics Files 8-K — Jun 13, 2025 Risk: low
Werewolf Therapeutics, Inc. filed an 8-K on June 13, 2025, reporting events as of June 12, 2025. The filing indicates amendments to articles of incorporation or
Werewolf Therapeutics Faces Delisting Concerns — May 15, 2025 Risk: high
Werewolf Therapeutics, Inc. filed an 8-K on May 15, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule or standard, with the e
Werewolf Therapeutics Announces Leadership Changes — Feb 24, 2025 Risk: medium
Werewolf Therapeutics, Inc. announced on February 19, 2025, the departure of its Chief Medical Officer, Dr. Rahul Chaturvedi. The company also reported the elec
Werewolf Therapeutics Acquired — Nov 12, 2024 Risk: medium
Werewolf Therapeutics, Inc. (HOWL) announced on November 12, 2024, that it has entered into a definitive agreement to be acquired by a third party. The filing d
Werewolf Therapeutics Files 8-K — Jun 25, 2024 Risk: low
On June 25, 2024, Werewolf Therapeutics, Inc. filed an 8-K report. The filing primarily concerns the company's financial statements and exhibits, along with oth
Werewolf Therapeutics Files 8-K — Jun 3, 2024 Risk: low
Werewolf Therapeutics, Inc. filed an 8-K on June 1, 2024, to report its current status. The filing confirms the company's principal executive offices are locate
Werewolf Therapeutics Files 8-K on Shareholder Vote Matters — May 28, 2024 Risk: low
Werewolf Therapeutics, Inc. filed an 8-K on May 28, 2024, reporting on matters submitted to a vote of security holders as of May 24, 2024. The filing details th
Werewolf Therapeutics Files 8-K for 'Other Events' and Exhibits — Feb 9, 2024 Risk: low
Werewolf Therapeutics, Inc. filed an 8-K on February 9, 2024, to report 'Other Events' and 'Financial Statements and Exhibits.' This filing indicates that the c
Werewolf Therapeutics Files Routine 8-K for Disclosure & Exhibits — Jan 8, 2024
Werewolf Therapeutics, Inc. filed an 8-K on January 8, 2024, primarily to disclose information under Regulation FD and to provide financial statements and exhib
Werewolf Therapeutics Updates Executive Compensation Arrangements — Jan 4, 2024
Werewolf Therapeutics, Inc. filed an 8-K on January 4, 2024, to report changes in its executive compensation arrangements. This filing, under Item 5.02, indicat

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX